Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), a leader in advanced cell therapy and immunotherapy research, is proud to announce that Dr. Lindsay Davies, the company's Chief Scientific Officer (CSO) and ISCT Europe Regional Secretary, serves as Co-Chair together with Dr. Massimiliano Gnecchi of the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden, from September 4-6.
"We are thrilled to have Dr. Davies representing NextCell Pharma at such an influential event," says Mathias Svahn, CEO of NextCell Pharma AB. "Her expertise in cell therapy and her leadership within ISCT underscore our company's commitment to advancing the science and therapeutic potential of cell-based treatments. This meeting is a great opportunity to showcase the progress NextCell is making in the field of advanced therapies, in particular the 5-year efficacy data with a single infusion of ProTrans for treatment of type-1 diabetes."
The ISCT Europe 2024 Regional Meeting brings together leading researchers, clinicians, and industry professionals from around the world to discuss the latest advances and challenges in the field of cell and gene therapy. This prestigious event focuses on cutting-edge scientific breakthroughs, regulatory trends, and innovative approaches to translating research into clinical applications, aiming to accelerate the development of new therapies for patients.
Dr. Lindsay Davies, in her dual role as CSO of NextCell Pharma AB and ISCT Europe Regional Secretary, has played a pivotal role in organizing the event and will be involved heavily with and steering the discussions during the event. Her leadership has been instrumental in shaping the program, which features high-profile speakers and interactive sessions addressing the most pressing issues in the rapidly evolving field of regenerative medicine.
The ISCT Europe 2024 Regional Meeting covers a wide range of topics, including innovations in stem cell therapies, gene editing technologies, regulatory hurdles, and strategies for commercialization. The event provides a platform for collaboration among industry leaders, academic institutions, and regulatory bodies to further the development of next-generation therapies aimed at treating chronic diseases and those indications with unmet medical needs.
NextCell Pharma AB continues to be at the forefront of cell therapy development with its lead product candidate ProTrans, a mesenchymal stromal cell-based therapy designed to treat autoimmune diseases such as type 1 diabetes. The company remains dedicated to pushing the boundaries of regenerative medicine through scientific innovation, clinical research, and partnerships with leading organizations in the biotech sector.
About ISCT
The International Society for Cell and Gene Therapy (ISCT) is a global association with a focus on driving the translation of scientific research into clinical applications of cell and gene therapies. With over 1,700 members in 50+ countries, ISCT connects academic, regulatory, and commercial stakeholders to advance the field of regenerative medicine.